Patient characteristics
| . | All . | Marrow . | Blood . | P . |
|---|---|---|---|---|
| No. | 77 | 35* | 42 | |
| Female (%) | 30 (39) | 10 (29) | 20 (48) | .089 |
| Age, y (range) | 26 (16-59) | 25 (17-53) | 32 (16-59) | .01 |
| Presentation leukocyte count (range) | 7.6 (0.7-900) | 12.2 (0.9-900) | 4.4 (0.7-602) | .65 |
| Karyotype (%) | .25 | |||
| t(9;22)† | 6 (8) | 4 (11) | 2 (5) | |
| t(4;11) | 3 (4) | 1 (3) | 2 (5) | |
| Other clonal | 26 (34) | 9 (26) | 17 (40) | |
| Normal | 27 (35) | 11 (31) | 16 (38) | |
| Not available | 15 (19) | 10 (29) | 5 (12) | |
| CNS disease at presentation (%) | 2 (3) | 1 (3) | 1 (2) | .89 |
| Immunophenotype (%) | .11 | |||
| Common | 50 (65) | 18 (51) | 32 (76) | |
| T | 14 (18) | 9 (26) | 5 (12) | |
| Null | 8 (10) | 4 (11) | 4 (10) | |
| B | 3 (4) | 3 (9) | 0 | |
| Unknown | 2 (3) | 1 (3) | 1 (2) | |
| Induction therapy (%) | < .0001 | |||
| MRC UKALL X (or similar) | 49 (63) | 34 (97) | 15 (36) | |
| MRC UKALL XII (or similar) | 28 (37) | 1 (3) | 27 (64) | |
| CR-transplantation interval, wk (range) | 16 (1-90) | 15 (5-69) | 18 (1-90) | .96 |
| Conditioning regimen (%) | < .0001 | |||
| Melphalan-TBI | 35 (45) | 35 (100) | ||
| Melphalan alone | 42 (55) | 42 (100) |
| . | All . | Marrow . | Blood . | P . |
|---|---|---|---|---|
| No. | 77 | 35* | 42 | |
| Female (%) | 30 (39) | 10 (29) | 20 (48) | .089 |
| Age, y (range) | 26 (16-59) | 25 (17-53) | 32 (16-59) | .01 |
| Presentation leukocyte count (range) | 7.6 (0.7-900) | 12.2 (0.9-900) | 4.4 (0.7-602) | .65 |
| Karyotype (%) | .25 | |||
| t(9;22)† | 6 (8) | 4 (11) | 2 (5) | |
| t(4;11) | 3 (4) | 1 (3) | 2 (5) | |
| Other clonal | 26 (34) | 9 (26) | 17 (40) | |
| Normal | 27 (35) | 11 (31) | 16 (38) | |
| Not available | 15 (19) | 10 (29) | 5 (12) | |
| CNS disease at presentation (%) | 2 (3) | 1 (3) | 1 (2) | .89 |
| Immunophenotype (%) | .11 | |||
| Common | 50 (65) | 18 (51) | 32 (76) | |
| T | 14 (18) | 9 (26) | 5 (12) | |
| Null | 8 (10) | 4 (11) | 4 (10) | |
| B | 3 (4) | 3 (9) | 0 | |
| Unknown | 2 (3) | 1 (3) | 1 (2) | |
| Induction therapy (%) | < .0001 | |||
| MRC UKALL X (or similar) | 49 (63) | 34 (97) | 15 (36) | |
| MRC UKALL XII (or similar) | 28 (37) | 1 (3) | 27 (64) | |
| CR-transplantation interval, wk (range) | 16 (1-90) | 15 (5-69) | 18 (1-90) | .96 |
| Conditioning regimen (%) | < .0001 | |||
| Melphalan-TBI | 35 (45) | 35 (100) | ||
| Melphalan alone | 42 (55) | 42 (100) |
Three patients with lymphoblastic lymphoma and bone marrow involvement who were included in our prior report have been excluded here.
Six patients had Ph+ disease detected on conventional cytogenetic studies (G-banding).
Reverse transcription–polymerase chain reaction was not performed routinely. It is therefore possible that the actual proportion of patients with Ph+ disease may be higher.